46-60 of 183
Improving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
Living RheumImproving Risk Stratification in Lupus Nephritis: The Role of Urinary Biomarkers
Rethinking Lupus Nephritis: Targeting Immune Dysfunction
Living RheumRethinking Lupus Nephritis: Targeting Immune Dysfunction
Joan Merrill, MD
Enhancing IgAN Care: The Importance of a Proactive Approach
Clinician's RoundtableEnhancing IgAN Care: The Importance of a Proactive Approach
Gates B. Colbert, MD
Suneel Udani, MD
Navigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
Clinician's RoundtableNavigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
Charles Turck, PharmD, BCPS, BCCCP
Jonathan Barratt, MD, PhD
Shikha Wadhwani, MD
Deciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
Clinician's RoundtableDeciphering the Link: Proteinuria and eGFR Dynamics in IgAN and FSGS
Gates B. Colbert, MD
Jonathan Barratt, MD, PhD
Proteinuria in CKD Progression: Understanding Its Role and Monitoring Strategies
Clinician's RoundtableProteinuria in CKD Progression: Understanding Its Role and Monitoring Strategies
Gates B. Colbert, MD
Jared Hassler, MD
- advertisement
Innovations in IgAN Care: Addressing Challenges with Therapeutic Advances
Clinician's RoundtableInnovations in IgAN Care: Addressing Challenges with Therapeutic Advances
Charles Turck, PharmD, BCPS, BCCCP
Pietro A. Canetta, MD
Moving Beyond Immunosuppressive Therapy in IgAN
Clinician's RoundtableMoving Beyond Immunosuppressive Therapy in IgAN
Gates B. Colbert, MD
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Identifying C3G: Key Diagnostic Considerations and Challenges
On the Frontlines of C3GIdentifying C3G: Key Diagnostic Considerations and Challenges
Anuja Java, MD
Transforming C3G Care: New Advances in Targeted Treatment
On the Frontlines of C3GTransforming C3G Care: New Advances in Targeted Treatment
Anuja Java, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
- advertisement
Osteoporosis in CKD: Closing the Gaps in Diagnosis and Treatment
On the Frontlines of OsteoporosisOsteoporosis in CKD: Closing the Gaps in Diagnosis and Treatment
Ryan Quigley
Charles Ginsberg, MD
TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Optimizing C3G Management: The Power of Lifestyle Changes and Supportive Care
On the Frontlines of C3GOptimizing C3G Management: The Power of Lifestyle Changes and Supportive Care
Richard Lafayette, MD, FACP